Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cumberland Pharmaceuticals

4.67
+0.17503.90%
Volume:11.94K
Turnover:55.49K
Market Cap:65.16M
PE:-10.12
High:4.75
Open:4.57
Low:4.57
Close:4.49
Loading ...

Fight Dmd Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

THOMSON REUTERS
·
20 Mar

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

PR Newswire
·
20 Mar

Cumberland Pharmaceuticals Full Year 2024 Earnings: US$0.46 loss per share (vs US$0.44 loss in FY 2023)

Simply Wall St.
·
13 Mar

Cumberland Pharmaceuticals: Key Insights from Earnings Call

TIPRANKS
·
06 Mar

Q4 2024 Cumberland Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
05 Mar

Cumberland Pharmaceuticals Inc (CPIX) Q4 2024 Earnings Call Highlights: Revenue Growth and ...

GuruFocus.com
·
05 Mar

Cumberland Pharmaceuticals Reports Revenue Growth and Strategic Advances

TIPRANKS
·
05 Mar

Cumberland: Q4 Earnings Snapshot

Associated Press Finance
·
05 Mar

Cumberland Q4 Adj EPS $(0.02) Up From $(0.11) YoY, Sales $10.44M Up From $9.35M YoY

Benzinga
·
05 Mar

Cumberland Pharmaceuticals Q4 Revenue USD 10.4 Million

THOMSON REUTERS
·
05 Mar

Cumberland options imply 26.1% move in share price post-earnings

TIPRANKS
·
05 Mar

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

PR Newswire
·
26 Feb

BRIEF-Cumberland Pharmaceuticals Inc -Vibativ Receives Marketing Approval In China

Reuters
·
18 Feb

Cumberland Pharmaceuticals' Pneumonia Injection Receives Approval in China

MT Newswires Live
·
18 Feb

Cumberland Pharmaceuticals Inc -Vibativ Receives Marketing Approval in China

THOMSON REUTERS
·
18 Feb

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

PR Newswire
·
18 Feb

Cumberland Pharmaceuticals Inc - Increases Max Aggregate Shares Offering Price to $10 Million

THOMSON REUTERS
·
15 Feb

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

Benzinga
·
05 Feb

BRIEF-Cumberland Pharmaceuticals Announces Phase 2 Fight Dmd Trial Results For Duchenne Muscular Dystrophy Heart Disease

Reuters
·
04 Feb

Cumberland reports ‘positive’ results from Phase 2 FIGHT DMD trial

TIPRANKS
·
04 Feb